'Some Hope Is Better Than Having No Hope'

President Trump was elected in 2024 on the promise that he would fix the economy. Now, a new poll from The New York Times/Siena reveals that the issue may be driving voters away.Nate Cohn, the chief political analyst at The Times, explains what the poll tells us.Guest: Nate Cohn, ...  Show more

For years, social media companies have relied on an impenetrable first amendment protection to shield them from legal claims that their products are dangerous to children.But now, a cluster of plaintiffs are trying a different tact.Cecilia Kang, who covers technology, explains wh ...  Show more

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

An overwhelming demand for ADHD diagnoses has left the NHS struggling to keep up. What’s behind the rise?

Content warning: This episode contains mentions of suicidal thoughts and eating disorders.

This podcast was brought to you thanks to the s ...